MedTrace Logo

Testosterone, Cognition, Ageing, and Cancer

NCT03452436 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 133

Last updated 2020-03-25

No results posted yet for this study

Summary

The primary aim of the study is - in a prospective controlled design - to examine whether treatment-induced decreases in testosterone acts as a mechanism of cancer-related cognitive impairment (CRCI) in testicular and prostate cancer patients.

Secondary aims are 1) to explore whether decreases in testosterone interacts with increasing age to cause more severe CRCI in older patients, 2) to explore underlying neurophysiological (brain morphology) mechanisms of CRCI, and 3) to evaluate selected genetic variants as possible moderators of CRCI.

Conditions

  • Cancer-related Cognitive Impairment

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Cecilie D R Clausen, MSc · Unit for Psychooncology & Health Psychology, Department of Oncology, Aarhus University

  • Robert Zachariae, Professor, DMSc · Unit for Psychooncology & Health Psychology, Department of Oncology, Aarhus University

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-12
Primary Completion
2020-03-01
Completion
2020-03-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03452436 on ClinicalTrials.gov